Treatment of Rheumatoid Arthritis (RA)

Goals and Overall Strategy

1. Non-pharmacologic measures

• Patient education, smoking cessation (smoking worsens disease severity and reduces DMARD response)
• Physical and occupational therapy to preserve joint function and muscle strength
• Splinting and assistive devices for affected joints

2. Bridging therapy (symptom control while DMARDs take effect)

• NSAIDs: control pain/stiffness but do not alter disease progression; watch for GI and cardiovascular risk
• Glucocorticoids (e.g., low-dose prednisone): rapid anti-inflammatory bridge during DMARD initiation, or for flares. Long-term use raises risk of osteoporosis (glucocorticoid-induced), so bisphosphonates, denosumab, or teriparatide should be considered for prevention in higher-risk patients - Harrison's, Ch. 370.

3. Conventional synthetic DMARDs (csDMARDs) - first line

4. Biologic DMARDs (added when csDMARD response is inadequate)

• TNF inhibitors (etanercept, infliximab, adalimumab, certolizumab, golimumab) - first biologics approved (1999), often combined with methotrexate for superior efficacy over monotherapy
• Abatacept (T-cell costimulation blocker, blocks CD28-CD80/86 interaction) - the AGREE trial in MTX-naive early erosive RA showed higher DAS28-CRP remission (41.4% vs 23.3%) and less radiographic progression than methotrexate alone; also showed a better safety profile than infliximab (fewer serious infections, adverse events) - Rheumatology, 2-Volume Set (2022, Elsevier), p. 627.
• Rituximab (anti-CD20, B-cell depletion) - typically for TNF-inhibitor failures
• Tocilizumab/sarilumab (IL-6 receptor blockers) - can be used as monotherapy if MTX is not tolerated
• Biosimilars - now widely available with comparable efficacy/safety to reference biologics

5. Targeted synthetic DMARDs

• JAK inhibitors (tofacitinib, baricitinib, upadacitinib) - oral small molecules for csDMARD/biologic failures; carry a boxed warning for cardiovascular events, malignancy, and thrombosis in at-risk populations (per FDA safety review), so are generally reserved after TNF-inhibitor failure in higher-risk patients

6. Surgical management

Monitoring and safety

Recent guideline evidence

• GUIPCAR 2025 Spanish guidelines (PMID: 41535165) and the 2024 Chinese RA guidelines (PMID: 39802551) reaffirm methotrexate as first-line therapy with early treat-to-target escalation to biologic/targeted synthetic DMARDs.
• The Canadian Rheumatology Association Living Guidelines (PMID: 37527865) and a 2023 systematic review of core RA recommendations (PMID: 37291382) similarly emphasize methotrexate, hydroxychloroquine, and sulfasalazine as core conventional agents, consistent with the textbook material above - no major contradictions found, but these are worth reviewing directly if you need the latest dosing/sequencing nuances.

Methotrexate: Dosage and Usage in Rheumatoid Arthritis

Mechanism (brief)

Place in therapy

Dosage

• Route/schedule: Given as a single weekly dose (occasionally split into 3 doses 12 hours apart over 24 hours in some regimens) - never taken daily.
• Starting dose: Typically 7.5-15 mg/week orally, titrated ("ramped up") based on response and tolerability.
• Dose range: 5-25 mg/week. High-dose therapy (20-25 mg/week) is more effective than low-dose (5-15 mg/week), but dosing is escalated gradually while monitoring for dose-dependent toxicity - Goldman-Cecil Medicine, Ch. 28, p. 2806.
• Route options: Oral absorption is dose-dependent and variable between individuals. Subcutaneous injection improves bioavailability, reduces GI side effects, and is often effective when oral therapy has a suboptimal response or is poorly tolerated.
• Renal adjustment: Methotrexate is cleared by glomerular filtration and active tubular secretion, so the dose must be reduced in renal impairment (including the elderly), and previously stable patients can develop toxicity if renal function worsens.

Folic acid co-therapy

Combination use

• Oral triple therapy: methotrexate + hydroxychloroquine + sulfasalazine, used when methotrexate monotherapy is insufficient.
• Biologic/targeted synthetic combinations: methotrexate is commonly continued alongside a TNF inhibitor or JAK inhibitor, since combination therapy generally outperforms biologic monotherapy.
• It is also FDA-approved for polyarticular juvenile idiopathic arthritis and psoriatic arthritis, where it treats peripheral arthritis/psoriasis but not enthesitis, dactylitis, or axial disease.

Toxicity and monitoring

Contraindications

• Absolute contraindication in pregnancy (teratogenic, can cause fetal death) and breastfeeding - Goldman-Cecil Medicine; Harrison's.
• Avoid in significant renal impairment or pre-existing liver disease; avoid alcohol while on therapy.
• Use caution in diabetic or obese patients (higher hepatotoxicity risk, notably documented in psoriasis populations).

Recent evidence context

Case Considerations: 65-Year-Old Obese Female with Rheumatoid Arthritis

1. Confirm the diagnosis and rule out mimics

2. Baseline workup before starting therapy

• CBC, renal function (eGFR - critical in this age group), LFTs, albumin
• Hepatitis B/C screening, TB screening (if biologics being considered)
• Lipid panel, blood pressure, fasting glucose (obesity + RA both independently raise cardiovascular risk, and this compounds)
• Baseline DEXA scan - postmenopausal women have elevated osteoporosis/fracture risk, which is further increased by RA-related inflammation and any glucocorticoid use

3. DMARD therapy - methotrexate with age-adjusted caution

• Start at a lower initial dose (e.g., 7.5-10 mg/week) rather than the higher end of range, since renal clearance of methotrexate declines with age and toxicity risk rises accordingly.
• Titrate slowly while monitoring CBC and AST/ALT every 8-12 weeks once stable (more frequently at initiation and after dose changes).
• Folic acid co-therapy (1-4 mg/day or 5 mg/week) as usual to reduce GI/hepatic toxicity.
• Renal function should be rechecked regularly - previously stable elderly patients can develop toxicity if GFR falls - Goldman-Cecil Medicine, Ch. 243.

4. Bridging glucocorticoids - use cautiously

5. NSAIDs - minimize use

6. Obesity-specific implications

• Obesity is independently associated with higher RA disease activity and lower rates of achieving remission, and with reduced response to TNF-inhibitor biologics specifically (pharmacokinetic dilution and inflammatory adipokine effects) - Rheumatology, 2-Volume Set (2022, Elsevier); Firestein & Kelley's Textbook of Rheumatology.
• Weight management (diet, supervised exercise/physical therapy) should be part of the plan - it improves both disease activity and cardiovascular risk profile, and may improve response to therapy.
• Cardiovascular risk from RA and obesity are additive - lipid and blood pressure monitoring should be routine, and statin therapy considered per standard CV risk calculators adjusted for RA (many guidelines apply a multiplier to standard risk scores in RA patients).

7. If escalation to biologic/targeted therapy is needed

• TNF inhibitors are generally reasonable, though obesity may blunt response - watch disease activity scores closely and consider dose/interval adjustment or an alternative mechanism (e.g., abatacept, IL-6 inhibitor) if response is inadequate.
• JAK inhibitors (tofacitinib, baricitinib, upadacitinib) warrant more caution here: the ORAL Surveillance trial and subsequent FDA boxed warning identified increased risk of major cardiovascular events, malignancy, venous thromboembolism, and death specifically in patients ≥65 years old (and current/past smokers). Given her age, JAK inhibitors would typically be reserved for after TNF-inhibitor failure, with a frank discussion of this risk, rather than used as an early-line biologic choice.

Monitoring summary for this patient

Recent evidence to flag